State of Wyoming Purchases New Holdings in Kura Oncology, Inc. $KURA

State of Wyoming purchased a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,347 shares of the company’s stock, valued at approximately $48,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KURA. Price T Rowe Associates Inc. MD raised its position in Kura Oncology by 18.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 28,070 shares of the company’s stock worth $245,000 after acquiring an additional 4,344 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in Kura Oncology during the fourth quarter worth $130,000. BNP Paribas Financial Markets raised its position in Kura Oncology by 969.9% during the fourth quarter. BNP Paribas Financial Markets now owns 163,559 shares of the company’s stock worth $1,425,000 after acquiring an additional 148,272 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of Kura Oncology by 172.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company’s stock valued at $10,027,000 after buying an additional 727,987 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in shares of Kura Oncology by 48.6% in the fourth quarter. Deutsche Bank AG now owns 64,623 shares of the company’s stock valued at $563,000 after buying an additional 21,135 shares during the last quarter.

Insider Buying and Selling at Kura Oncology

In related news, CEO Troy Edward Wilson purchased 50,000 shares of Kura Oncology stock in a transaction dated Monday, September 8th. The shares were bought at an average cost of $8.20 per share, for a total transaction of $410,000.00. Following the purchase, the chief executive officer owned 100,968 shares in the company, valued at approximately $827,937.60. This trade represents a 98.10% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.40% of the company’s stock.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $8.01 on Wednesday. The stock has a market capitalization of $695.27 million, a PE ratio of -3.54 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. The business has a fifty day moving average price of $6.76 and a two-hundred day moving average price of $6.57. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $21.40.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to the consensus estimate of $64.95 million. As a group, equities analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

KURA has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 26th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Friday, June 20th. Mizuho cut their price objective on Kura Oncology from $32.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, May 19th. Guggenheim initiated coverage on Kura Oncology in a research report on Thursday, September 4th. They issued a “neutral” rating for the company. Finally, Wall Street Zen raised Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.10.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.